Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials

被引:0
|
作者
Menezes, Michelle Santos [1 ]
Doria, Grace Anne Azevedo [1 ]
Valenca-Feitosa, Fernanda [2 ]
Pereira, Sylmara Nayara [2 ]
Silvestre, Carina Carvalho [3 ]
de Oliveira, Alfredo Dias [2 ]
Lobo, Iza Maria Fraga [4 ]
Quintans-Junior, Lucindo Jose [5 ,6 ]
机构
[1] Univ Fed Sergipe, Cidade Univ Prof Jose Aloisio Campos, BR-49100000 Jardim Rosa Elze, Sao Cristovao, Brazil
[2] Univ Fed Sergipe, Dept Pharm, Lab Teaching & Res Social Pharm LEPFS, Cidade Univ Prof Jose Aloisio Campos, BR-49100000 Jardim Rosa Elze, Sao Cristovao, Brazil
[3] Univ Fed Juiz de Fora, Governador Valadares Campus,Univ Campus,Rua Jose L, BR-36036900 Juiz de Fora, MG, Brazil
[4] Univ Fed Sergipe, Univ Hosp, R Claudio Batista Palestine, BR-49060676 Aracaju, SE, Brazil
[5] Fed Univ Sergipe DFS UFS, Physiol Dept, Jardim Rosa Elze, Sao Cristovao, Brazil
[6] Univ Fed Sergipe, Lab Neurosci & Pharmacol Tests LANEF, Jardim Rosa Elze, Rua Marechal Rondon S-N, BR-49100000 Jardim Rosa Elze, Sao Cristovao, Brazil
来源
EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY | 2024年 / 14卷
关键词
Patient safety; Medication errors; Hospital; High-alert medication or dangerous drugs; SEVERE APLASTIC-ANEMIA; ANTITHYMOCYTE GLOBULIN; RAPID TRANQUILIZATION; ATRIAL-FIBRILLATION; SKIN NECROSIS; CYCLOSPORINE; HALOPERIDOL; MORTALITY;
D O I
10.1016/j.rcsop.2024.100435
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: High-alert medication (HAM) is more predictable to cause significant harm to the patient, even when used as intended. The damage related to the HAM lead not only suffering to the patient, but also raise the additional costs associated with care. Objective: Evaluate the incidence of drug-related adverse events related to the use of high-alert medications. Methods: It was conducted an active search for information through COCHRANE databases, LILACS, SciELO, SCOPUS, PubMed/MEDLINE and WEB OF SCIENCE. The search strategy included the following terms: "Patient safety", "Medication errors" and "Hospital" and "High Alert Medications" or "Dangerous Drugs" in different combinations. Then two reviewers independently conducted a preliminary evaluation of relevant titles, abstracts and finally full-text. Studies quality was evaluated according to PRISMA declaration. Results: The systematic review evaluated seven articles, which showed that only 11 HAM identified in the literature could have serious events. The most frequently cited were warfarin (22.2%) which progressed from deep vein thrombosis to gangrene, suggesting lower initial doses, followed by cyclophosphamide (22.2%) and cyclosporine (22.2%) which presented invasive fungal infection and death. In addition to these, morphine was compared with its active metabolite (M6G), with M6G causing fewer serious clinical events related to nausea and vomiting, reducing the need for concomitant use of antiemetics. Conclusions: The most reported drug classes in the articles included that were related to incidence of drug-related adverse events in use of high-alert medications: morphine, M6G-glucuronide, haloperidol, promethazine, ivabradine, digoxin, warfarin, ximelagatran, cyclophosphamide, cyclosporine, and ATG. The formulate protocols for the use of these medications, with importance placed on evaluating, among the classes, the medication that causes the least harm.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Adverse kidney related events following targeted therapies in lung cancer: a systematic review and network meta-analysis of randomized controlled trials
    Ren, Song
    Wang, Wei
    Yao, Xiaoxiu
    Fang, Wenyan
    Li, Guisen
    Feng, Yunlin
    Xia, Min
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [32] Drug-Related Pyroglutamic Acidosis: Systematic Literature Review
    Scafetta, Tessa
    Kovacs, Orsolya
    Milani, Gregorio P.
    Bronz, Gabriel
    Lava, Sebastiano A. G.
    Betti, Celine
    Vanoni, Federica
    Bianchetti, Mario G.
    Fare, Pietro B.
    Camozzi, Pietro
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (19)
  • [33] Drug-related problems in cancer patients: A systematic review
    Venugopal, Jayalakshmi
    Shalini, S.
    Rajasekaran, A.
    Karnan, Deepika
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 562 - 571
  • [34] Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review
    Marangu, Diana
    Kovacs, Stephanie
    Walson, Judd
    Bonhoeffer, Jan
    Ortiz, Justin R.
    John-Stewart, Grace
    Horne, David J.
    VACCINE, 2015, 33 (41) : 5333 - 5341
  • [35] The incidence of stoma-related morbidity - a systematic review of randomised controlled trials
    Malik, T. A. M.
    Lee, M. J.
    Harikrishnan, A. B.
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 35 - 35
  • [36] Parental reporting of adverse drug events and other drug-related problems in children in Finland
    L. Lindell-Osuagwu
    K. Sepponen
    S. Farooqui
    H. Kokki
    K. Hämeen-Anttila
    K. Vainio
    European Journal of Clinical Pharmacology, 2013, 69 : 985 - 994
  • [37] Parental reporting of adverse drug events and other drug-related problems in children in Finland
    Lindell-Osuagwu, L.
    Sepponen, K.
    Farooqui, S.
    Kokki, H.
    Hameen-Anttila, K.
    Vainio, K.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (04) : 985 - 994
  • [38] Clinical Effectiveness and Adverse Events of Bee Venom Therapy: A Systematic Review of Randomized Controlled Trials
    Jang, Soobin
    Kim, Kyeong Han
    TOXINS, 2020, 12 (09)
  • [39] Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Sterling, Lee H.
    Windle, Sarah B.
    Filion, Kristian B.
    Touma, Lahoud
    Eisenberg, Mark J.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (02):
  • [40] Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review
    Chowers, Michal Y.
    Gottesman, Bat Sheva
    Leibovici, Leonard
    Pielmeier, Ulrike
    Andreassen, Steen
    Paul, Mical
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) : 239 - 250